Posted by Michael Wonder on 31 Mar 2022
Chugai obtains regulatory approval for Vabysmo, the first bispecific antibody in ophthalmology, for neovascular age-related macular degeneration and diabetic macular oedema
28 March 2022 - The bispecific antibody inhibits two disease pathways that drive nAMD and DME by blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A.
28, 2022 -- Chugai Pharmaceutical announced that it has obtained regulatory approval today from the MHLW for Vabysmo (faricimab), an anti VEGF/anti Ang-2 bispecific antibody for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularisation and diabetic macular oedema
